Dose dense Dreifach*Melphalan100 for multiple myeloma.

被引：0
|
作者：
Berz, David
McCormack, Elise M.
Winer, Eric S.
Karwan, Patricia
Colvin, Gerald
Rathore, Ritesh
Lum, Larry
Abedi, Mehrdad
Elfenbein, Gerald
Quesenberry, Peter J.
机构：
[1] Brown Univ, Providence, RI 02912 USA
[2] Roger Williams Med Ctr, Providence, RI USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.5465.5465
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5465
引用
收藏
页码：462B / 462B
页数：1
相关论文
共 50 条
  • [31] MODELING THROMBOCYTOPENIA AS A PREDICTOR OF OUTCOMES FOLLOWING SINGLE, HIGH--DOSE MELPHALAN AND STEM CELL TRANSPLANT IN MULTIPLE MYELOMA.
    Irby, D.
    Cottini, F.
    Hade, E.
    Hofmeister, C.
    Phelps, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S27 - S27
  • [32] High-dose idarubicine, busulphan and melphalan for autologous stem cell transplantation in multiple myeloma. Comparison with an historical control
    Capria, S
    Ribersani, M
    Ferrazza, G
    Micozzi, A
    Petrucci, MT
    Simone, F
    Torromeo, MC
    Trisolini, SM
    Mandelli, F
    Meloni, G
    BONE MARROW TRANSPLANTATION, 2003, 31 : S81 - S82
  • [33] High-dose melphalan 180 mg/m2 with autologous blood stem cell transplantation for multiple myeloma.
    Dimopoulos, MA
    Papadimitriou, C
    Kostis, E
    Kouvelis, V
    Zomas, A
    Grigoraki, V
    Vervessou, E
    Sakarellou, N
    Panayiotides, P
    Anagnostopoulos, N
    BLOOD, 1999, 94 (10) : 399B - 399B
  • [34] HIGH-DOSE MELPHALAN (HDM) IN MULTIPLE-MYELOMA
    SELBY, P
    POWLES, R
    ROBINSON, B
    VINCENT, M
    MCELWAIN, TJ
    BRITISH JOURNAL OF CANCER, 1984, 50 (02) : 247 - 247
  • [35] DOSE INTENSITY ANALYSIS OF MELPHALAN AND PREDNISONE IN MULTIPLE-MYELOMA
    PALMER, M
    BELCH, A
    HANSON, J
    BROX, L
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (06): : 414 - 418
  • [36] A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.
    Qazilbash, Muzaffar H.
    Saliba, Rima M.
    Pelosini, Matteo
    Hosing, Chitra M.
    Mendoza, Floralyn L.
    Han, Eric
    Wang, Michael
    Weber, Donna M.
    Alousi, Amin M.
    Anderlini, Paolo
    Kebriaei, Partow
    Khouri, Issa F.
    Popat, Uday R.
    De Lima, Marcos
    Orlowski, Robert Z.
    Champlin, Richard E.
    Giralt, Sergio A.
    BLOOD, 2008, 112 (11) : 1140 - 1141
  • [37] Melphalan-induced DNA damage in vitro as predictor for clinical outcome in multiple myeloma.
    Dimopoulos, Meletios A.
    Souliotis, Vassilis L.
    Anagnostopoulos, Athanasios
    Bamia, Christina
    Pouli, Anastasia
    Baltadakis, Ioannis
    Terpos, Evangelos
    Kyrtopoulos, Soterios A.
    Sfikakis, Petros P.
    BLOOD, 2006, 108 (11) : 22A - 23A
  • [38] A prospective study of bortezomib in combination with melphalan and prednisone for patients with previously untreated multiple myeloma.
    Gasparetto, C
    Keogh, GP
    Gockerman, JP
    Horwitz, M
    Moore, JO
    DeCastro, C
    Diehl, L
    Davis, P
    Chao, N
    Rizzieri, DA
    BLOOD, 2005, 106 (11) : 379B - 379B
  • [39] High-dose melphalan and etoposide prior to autologous hematopoietic stem cell transplant is an effective regimen in the treatment of multiple myeloma.
    Briggs, AD
    Taylor, CW
    Sturm, TJ
    Shapiro, TW
    List, AF
    BLOOD, 1998, 92 (10) : 362B - 362B
  • [40] High-dose idarubicine, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study
    Meloni, G
    Capria, S
    Trasarti, S
    Ferrazza, G
    Micozzi, A
    Petrucci, MT
    Simone, F
    Trisolini, SM
    Mandelli, F
    BONE MARROW TRANSPLANTATION, 2000, 26 (10) : 1045 - 1049
12345